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Osteoporosis is defined as a skeletal disorder characterised by low bone 
mass and micro-architectural deterioration of bone tissue, with the overall 
focus on bone quality. It affects more than 75 million people worldwide, 
and cause people to become bedridden with life threatening secondary 
complications. 
 
An estimated 10 million South Africans, out of a population of 43 million 
people, are at high risk of developing osteoporosis. In South Africa 
osteoporosis affects one in three women over 50 and one in five men. 
Within one year after a hip fracture, up to 20% of the people die, 15-20% 
needs to be institutionalised and 50% of the remainder will not be able to 
lead an independent life. The number of fractures is two to three times 
higher in women than in men due to the hormonal changes that occur 
after menopause. 
 
The prevalence of osteoporosis increases markedly with age and, based 
on the bone mineral density at the femoral neck of the hip, approximately 
30% of Caucasian women, by age of 75 years will be classified as having 
osteoporosis. 
 
Dual-Energy X-ray Absorptiometry (DEXA) is the preferred method for 
measuring BMD. The results of the DEXA scan are scored in comparison 
with the BMD of young, healthy individuals, resulting in a measurement 
called a T-score. A T-score of –2.5 or lower is considered to be 
osteoporosis and T-scores between –0.1 and –2.5 are generally 
considered to show osteopenia. 
 
The aim of the study was to examine communication between referring 
physicians and patients who had been referred for a DEXA scan.  
SUMMARY 
  
A total of fifty patients were included in the study group. This was much smaller 
than was anticipated. The ideal would have been a much bigger sample group 
for a bigger representation of the population. Patients, who complied with the 
inclusion criteria and also gave their consent, were recruited between January 
2004 and November 2004. Not all the patients referred for a DEXA scan had the 
required low BMD. 
 
Bone scans were performed on the HOLOGIC 4500 QDR, a multiple 
detector, fan beam, Dual Energy X-ray Densitometer. The Hologic 4500 
QDR Bone Densitometer estimates the Bone Mineral Content (BMC) in 
grams, and the BMD in grams per cm2. The QDR 4500 uses a low level of 
X-rays with two different energies to estimate BMC and BMD. The 
radiation exposure at a distance of two metres from the equipment is less 
than one mR/hour. 
 
The age distribution of the study group ranged between 14 and 84 years 
(average age was 57,2 years). Out of the total of 50 patients, only one 
was male and the entire patient population was Caucasian. This may be 
due to the small sample size and inclusion/exclusion criteria. Concerning 
the references of the patient population, Universitas Academic Hospital 
(UAH) referred more than half of the patients (64%), while the other points 
of care referred only 36%. 
 
In this study, it was found that BMD results do influence the management 
of osteopenia/osteoporosis in the majority of patients and the test has a 
positive impact on the management of patients with this condition. There 
was however 22% of patients that did not receive feedback concerning 
the results of the DEXA and the necessary treatment. These findings also 
highlighted the fact that communication between physician and patient is 
 a very important component in using the information provided by this test 
to its full potential. 
 
The ideal is to identify a low BMD early enough to stop the damaging 
consequences thereof, but this is not always feasible due to the high 
costs involved in a DEXA scan. Access to treatment and care is also not 
readily available to a large section of the population and, in State 
Hospitals; the availability of drugs to treat osteoporosis is limited due to 
the high costs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Osteoporose is „n toestand wat gekenmerk word deur „n lae beenmassa 
en verlies aan beenweefsel. Die kwaliteit van been word ook daardeur 
beinvloed. Dit affekteer meer as 75 miljoen mense werêldwyd en kan die 
mobiliteit van „n persoon aantas met lewensbedreigende gevolge. 
 
Ongeveer 10 miljoen Suid-Afrikaners uit „n bevolking van 43 miljoen loop 
die risiko om osteoporose te ontwikkel. In Suid Afrika word ongeveer een 
uit elke drie vrouens deur osteoporosis geaffekteer en een uit elke vyf 
mans. Binne een jaar na „n heupfraktuur kan tot 20% van die pasiënte as 
gevolg daarvan sterf en 15-20% het versorging nodig. Die res van die 
pasiënte sal nie meer „n normale onafhanklike lewe na „n osteoporotiese 
fraktuur kan lei nie. Die aantal frakture in vrouens is twee tot drie keer 
hoër in as in mans as gevolg van die hormonale veranderinge na 
menopouse. 
 
Die voorkoms van osteoporose verhoog merkwaardig met ouderdom en 
wanneer daar na die minerale digtheid van die been by die femorale nek 
gekyk word, sal 30% blanke vrouens teen die ouderdom van 75 jaar met 
osteoporose geklassifiseer word. 
 
“Dual-Energy X-ray Absorptiometry” (DEXA) is tans die beste metode om 
die mineraaldigtheid van die been (BMD) te bepaal. Die resultate van die 
DEXA word vergelyk met die BMD van „n jong, gesonde individue en word 
uitgedruk as die “T-score”. „n “T-score” van –2.5 of laer, word aanvaar as 
osteoporose en „n “T-score” tussen –0.1 en –2.5 word beskou as 
osteopenies. 
 
Die doel van hierdie studie was om kommunikasie tussen die verwysende 
geneesheer en die verwyste pasiënt te evalueer. Is dit vir die pasiënt 
OPSOMMING 
 enigsins voordelig om vir „n DEXA te gaan in terme van terugvoering oor 
resultate en behandeling indien nodig. 
 
„n Totaal van 50 pasiënte was in die studie ingesluit. Die studiegroep is 
heelwat kleiner as waarvoor gehoop is en die ideaal sou wees om „n 
groter verteenwoordigend van die bevolking te kry. Pasiënte, tussen 
Januarie 2004 en November 2004, wat aan die insluitingskriteria voldoen 
het en ook toestemming gegee het, is gewerf. Nie alle pasiënte wat vir „n 
DEXA gestuur was, het die verlangde lae BMD gehad nie.  
 
Die prosedure is uitgevoer op „n HOLOGIC 4500 QDR DEXA 
skandeerder. Dit bereken die minerale inhoud van die been (BMC) in 
gram, en die BMD in gram per cm2. Die QDR 4500 gebruik „n lae dosis X-
strale met twee verskillende energievlakke om die minerale inhoud (BMC) 
en minerale dightheid (BMD) in been, te bereken. 
 
Die studiegroep se ouderdomsverspreiding het gewissel vanaf 14 tot 74 
jaar (gemiddelde ouderdom, 57,2 jaar). Slegs een pasiënt was manlik en 
die hele studiegroep was blanke pasiënte. Dit kan wees as gevolg van die 
klein pasiëntgroep en die insluitings-/uitsluitingskriteria. Verwysings het 
grootliks vanaf Universitas Akademiese Hospitaal(UAH) gekom (64%), 
met slegs 36% van die pasiënte vanaf verwysings buite UAH. 
 
In hierdie studie is gevind dat die BMD resultate die hantering van 
osteoporose/osteopenie beinvloed en vir die grootste deel van die 
pasiëntgroep het die uitvoer van die toets „n positiewe impak op die 
hantering van hulle lae BMD gehad. Daar was egter 22% van die 
pasiëntgroep wat geen terugvoer ontvang het met betrekking tot die 
uitslae van hulle BMD. 
 
 Hierdie bevindinge het dit weereens bevestig dat kommunikasie tussen 
die geneesheer en die pasiënt „n belangrike rol speel om die resultate 
verkry, ten volle te benut. 
 
Die ideaal sou wees om die lae BMD groep vroegtydig te kon identifiseer 
sodat nadelige gevolge van hierdie toestand vroegtydig gestop kan word. 
Dit is ongelukkig nie altyd uitvoerbaar weens die hoë koste verbonde aan 
„n DEXA prosedure. Toegang tot behandeling is vir „n groot deel van die 
bevolking nie altyd beskikbaar nie en in die staatshospitale is daar ook „n 
beperking op die beskikbaarheid van medikasie weens die hoë koste.  
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1.1 INTRODUCTION 
 
According to the Osteoporosis Foundation of South Africa, an 
estimated 10 million South Africans, out of a population of 43 
million people, are at high risk of developing osteoporosis (National 
Osteoporosis Foundation of South Africa, 2004). In South Africa 
osteoporosis affects one in three women over 50 (more than breast 
cancer) and one in five men. Within one year after a hip fracture, 
up to 20% of the people die, 15-20% need to be institutionalised 
and 50% of the remainder will not be able to lead an independent 
life. The number of fractures are two to three times higher in 
women than in men partly due to the hormonal changes that occur 
after menopause and partly because women have a lower peak 
bone mass. 
 
In the United States alone, osteoporosis causes approximately 1.5 
million fractures a year and is the leading cause of hip fractures 
(WomensHealthChannel.com, 2006). An estimated 10 million 
Americans have osteoporosis and another 18 million are likely to 
develop it. Eighty percent of those who have or will have 
osteoporosis are women. 
 
Osteoporosis is one of the world’s most devastating and common 
chronic diseases. It causes the bones to become fragile and more 
likely to break. In spite of the information available, osteoporosis is 
still not regarded as a health priority in South Africa and countless  
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sufferers are denied access to suitable treatment and care (HEALTH 
24.com, 2006). 
 
In South Africa malnutrition and infections (including the HIV/AIDS 
pandemic and tuberculosis) are plentiful; and due to this fact, 
osteoporosis is not at present regarded as a health priority. 
Unfortunately, access to treatment and care is also not available to 
a large section of the population; and, in State Hospitals, the 
availability of drugs to treat osteoporosis is limited due to the high 
costs (National Osteoporosis Foundation of South Africa, 2003).  
 
Until recently, osteoporosis was regarded as a “boring” disease, 
believed to be untreatable and the inevitable consequence of old 
age (Riggs and Melton, 1995). The treatment thereof was largely 
confined to patients with vertebral fracture syndrome. Hip and 
Colles’ fractures were usually ignored and the diagnosis thereof was 
limited to patients with non-traumatic vertebral fractures. This was 
largely because there was no effective way to measure bone 
density. 
 
In 1984, the National Institutes of Health (NIH) Consensus 
Development Conference in America recognized the magnitude of 
the problem and changed their view on osteoporosis (Riggs and 
Melton, 1995). It has become clear to physicians that there are 
effective strategies for treatment and prevention. In recent years 
interest in osteoporosis has increased dramatically due to the 
increased availability of treatments. 
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Public awareness of osteoporosis as a health issue has also 
increased. However, the usefulness of the patients’ test results 
depends on the communication between the physician and the 
patient. It is important to understand their test results when 
starting treatment after the bone densitometry (Fitt et al., 2001). 
  
At present Dual Energy X-ray Absorptiometry (DEXA) is the 
technique of choice in determining BMD, because of its ability to 
assess bone mass at both axial and appendicular sites, its high 
reproducibility, and the very low doses of radiation associated with 
it (Divittorio et al., 2006). The World Health Organization (WHO, 
2003), regards it as the preferred technique for diagnostic 
purposes. 
 
Osteoporosis is a disorder for which prevention is much better than 
treatment (Drife and Studd, 1990). Identifying individuals at risk of 
fracture, prior to fracture occurrence, is a strategy that must be 
evaluated on a population basis. 
 
Ignorance about osteoporosis is still common among health 
professionals, patients and the public; therefore education of all 
these groups is necessary, as osteoporosis is a very disabling 
disease and the emphasis must be on early diagnosis and 
intervention as this will be more cost effective than treatment 
(Jergas and Genant, 1993).  
 
A study conducted by Fitt et al. (2001) also investigated this 
hypothesis and recognised communication and the patient’s  
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understanding of the bone densitometry results as crit ical 
components in the initiation of therapy.  
 
 
1.2 AIM 
 
The aim of this study was to examine the communication between 
referring physicians and patients who had been referred for a DEXA 
scan. 
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2.1 INTRODUCTION 
 
The clinical significance of osteoporosis lies in the fractures that 
may occur (Kanis, 1994). These fractures are very disabling and 
can cause death. The major problem in the management of the 
disease today is that the diagnosis of osteoporosis is most 
frequently made only when a fracture has occurred. Bone loss is 
usually very slow and asymptomatic until a fracture has occurred. 
This means that the disorder has usually been present for many 
years before it is diagnosed. For this reason, early recognition of 
osteoporosis is important. 
 
 
2.2 EPIDEMIOLOGY 
 
Osteoporosis affects more than 75 million people worldwide, and 
apart from the fractures that occur, it can cause people to become 
bedridden with secondary complications (Zizic, 2004). These 
complications may be life threatening to the elderly.  
 
According to the International Osteoporosis Foundation (IOF) the 
number of osteoporotic fractures in 2000 in Europe alone were an 
estimated 3.79 million. A study conducted in Switzerland 
(Health24.com, 2006) showed that the annual costs of 
hospitalization for osteoporotic fractures were greater than those 
for myocardial infarction, stroke and breast cancer.  
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In the USA the fracture risk for Caucasians is higher than for the 
other ethnic groups. At least 1.5 million fractures each year in the 
USA are attributable to osteoporosis, including roughly 250 000 hip, 
250 000 wrist and 500 000 vertebral fractures (Melton et al., 1990). 
It is estimated that by the year 2010, 12 million people over the 
age of 50 will have osteoporosis and 40 million will have a low bone 
mass. By 2020, this is expected to increase to 14 million 
osteoporotic cases and 47 million cases of low bone mass.  
 
The prevalence of osteoporotic fractures in Caucasians and Asians 
in South Africa are similar to those reported from North America 
and Europe(National Osteoporosis Foundation South Africa, 2004). 
Black South African, however, have the lowest hip fracture 
prevalence in the world (National Osteoporosis Foundation South 
Africa, 2004). According to the Osteoporosis Foundation of South 
Africa (2004), there are an estimated 10 million people out of a 
population of 43 million people at high risk of developing osteoporosis. 
 
In Australia 1.9 million people had osteoporosis in 2002. It is 
projected that by 2006 this figure will be 2,2 million and in the year 
2021 it is expected to be 3 million people (National Osteoporosis 
Foundation of America, 2006). 
 
In 1995, osteoporosis caused more than 150 000 fractures in the 
United Kingdom alone (Compston et al., 1995). 
 
 Chapter 2                                                                                                                       p 9 
 
An IOF survey conducted in 11 countries showed that denial of 
personal risk by postmenopausal women; the lack of communication 
about osteoporosis with their physician, and restricted access to 
diagnosis and treatment before the first fracture result in under 
diagnosis and under treatment of the disease (International 
Osteoporosis Foundation, 2005). 
 
 
2.3 WHAT IS OSTEOPOROSIS? 
 
Osteoporosis is defined as a skeletal disorder characterized by low 
bone mass and micro-architectural deterioration of bone tissue 
(Figure 2.1), leading to an increase in bone fragility and 
susceptibility to fracture (O’Neill et al., 2004). With an overall focus 
on bone quality well (Bukata and Healey, 2005). 
 
Osteoporosis may present with low bone density and an 
osteoporotic fracture is one that occurs with minimal or no trauma, 
i.e. a fall from standing height or less (O’Neill et al., 2002). 
Because osteoporosis is characterized by a reduction in bone mass 
that comprises the biomechanical integrity of the skeleton, it leads 
to an increased risk of fractures. Any bone can be affected, but of 
special concern are fractures of the hip and spine. Fractures of the 
proximal femur (hip), the vertebrae (spine) and the distal forearm 
(Colles) are often linked with osteoporosis (Figure 2.2).  
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A hip fracture almost always requires hospitalization and/or major 
surgery. The more serious consequences of vertebral fractures may 
include loss of height, severe back pain and deformity. The 
condition develops without warning signs. Most people with 
osteoporosis do not realize they have the disease until a minor fall 
results in a broken hip, wrist or vertebra. Prevention of the disease 
and its associated fractures are essential for health, quality of life 
and independence among the elderly (World Health Organization, 
2003). 
 
 
 
                           
  
FIGURE 2.1 SEM of osteoporotic and of normal trabecular bone* 
(Compston et al., 1995). *SEM = scanning electron micrograph 
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Two types of bone are affected by Osteoporosis 
(WomensHealthChannel, 2006): 
 
 Cortical bone – the compact outer layer of the bone shaft, 
 Trabecular bone – a mesh like inner structure; is found in 
high percentages in the hip, spine, and wrist; is the most 
vulnerable to osteoporosis. 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.2 Typical sites of osteoporotic fractures: a) vertebrae; 
b) proximal femur; c) distal radius (Woolf, 1994) 
 
The prevalence of osteoporosis increases markedly with age in 
women and, based on the BMD at the femoral neck of the hip, 
approximately 30% of Caucasian women, by age of 75 years will be 
classified as having osteoporosis (World Health Organization, 
2003). 
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Because of the reduction in bone tissue, the bones most likely to 
break are the weight bearing bones like the hip, spine and 
sometimes the forearm (Figure 2.2). One out of every three 
westernised postmenopausal women will have a spinal fracture due 
to osteoporosis. Up to 20% of hip fracture victims die within a year. 
Among those living independently before a hip fracture, only half 
are able to do so after it (World Health Organization, 2003).  
 
Men generally have 20 percent greater BMD than women. Men with 
osteoporosis and low bone mass totalled over 14 million in 2002 
and this figure are expected to increase to over 17 million by 2010 
(National Osteoporosis Foundation of America, 2006). Black people 
have 20 percent greater bone density than Caucasians. Therefore, 
neither men nor black people are affected with osteoporosis as 
frequently as Caucasian women, although they can develop the 
disease (Zizic, 2004). 
 
BMD and bone strength change throughout life (Figure 2.3). Bone 
density increases during growth, especially in adolescence, and 
continues to increase in young adulthood even after maximum 
height is achieved (National Osteoporosis Foundation of America, 
1991). It peaks around age 30 for predominantly trabecular bones, 
such as the vertebrae, and somewhat later for predominantly 
cortical bones, such as the femur and radius. After bone density 
peaks, losses begin and continue throughout life. Lifetime losses 
range from 20% to 30% in men and 40% to 50% in women, and 
involve virtually all the skeletal sites.  
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FIGURE 2.3 Changes in Bone Mineral Density with age (Hough, 
2000). 
 
 
Fracture at any site increases the risk of subsequent fracture 
(Klotzbuecher et al., 2000) and up to 20% of women who have an 
incident vertebral fracture incur another fracture within one year 
(Lindsay et al., 2001). 
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2.4 DIAGNOSIS and ASSESSMENT  
 
Osteoporosis was not classified as a disease until relatively 
recently, since it was considered to be a condition that expressed 
itself as fractures (World Health Organization, 2003). Early 
osteoporosis is not usually diagnosed and remains asymptomatic, 
therefore it does not become clinically evident until fractures occur. 
 
Measurement of BMD is the most readily available, non-invasive 
method for assessing osteoporotic fracture risk and is 
recommended by the World Health Organization for diagnostic 
purposes (Divittorio et al., 2006). 
 
Bone density is a continuous variable; the lower the bone density, 
the higher the risk for fracture, and the higher the imperative to 
intervene with treatment. The cornerstone of diagnosis is the 
measurement of bone mineral density. Diagnostic thresholds (Table 
2.1) offered by the World Health Organization have been widely 
accepted (Kanis, 1994). 
 
The hip is the preferred site for diagnostic assessment, particularly 
in the elderly, and Dual-Energy X-ray Absorptiometry (DEXA) is the 
preferred method, although other sites and methods are useful in 
assessing the risk and, in some cases, the response to treatment 
(Kanis, 1994). The emphasis on hip measurement arises from the 
clinical importance of hip fracture and the strength of the 
relationship between BMD at this site and the risk of hip fracture.  
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Prospective studies have shown (Bacon, 1996; World health 
Organization, 2003; Woolf, 1994), however, that the risk of fracture 
in general increases progressively the lower the BMD, regardless of 
measurement site. For each standard deviation decrease in BMD, 
fracture risk increases by approximately 50%. The ability of BMD to 
predict hip fractures is better or at least as good as that of the 
measurement of blood pressure to predict a stroke. 
 
When historical, radiological or clinical findings suggest that 
osteoporosis is present; bone densitometry by the best available 
method is indicated to confirm or rule out the diagnosis. Currently, 
DEXA is the best practical method for measuring BMD. Additional 
biochemical or hormonal tests should also be considered to 
elucidate other factors that may be contributing to loss of bone 
density (Sturtridge et al., 1996). 
 
 
2.4.1 Bone densitometry is recommended in the presence of:  
 
 Radiographic evidence of osteopenia and/or vertebral 
deformity; 
 Loss of height, thoracic kyphosis (after radiographic 
confirmation of vertebrae deformity); 
 Previous low-trauma fragility fracture; 
 Prolonged therapy with corticosteroids (e.g. prednisolone 
at 7.5 mg daily for six months); 
 Premature menopause (age <45 years); 
 Prolonged secondary amenorrhoeas (>1 year); 
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 Primary or secondary hypogonadism; 
 Chronic disorders associated with osteoporosis; 
 A maternal history of hip fracture; 
 A low Body Mass Index (BMI). 
 
 
2.4.2 Sources of error in the diagnosis of osteoporosis by DEXA  
(Kanis, 1997). 
 
 Osteomalacia; 
 Osteoarthritis (spine but also hip); 
 Soft tissue calcification (especially the spine); 
 Overlying metal objects; 
 Contrast media; 
 Previous fracture (spine, hip and wrist); 
 Severe scoliosis; 
 Extreme obesity or ascites; 
 Vertebral deformities due to osteoarthritis or Scheuerman 
disease; 
 Inadequate reference ranges; 
 Inadequate operating procedures (e.g. calibration region 
selection, acquisition mode, positioning) (osteopenia).  
 
 
2.4.3 Site of bone measurements 
 
Although measurements at any particular site are significantly 
related to measurements at other sites in the same individual, this  
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does not mean that the choice of site is unimportant (Nordin, 
1994). 
 
Certain sites may be of greater diagnostic value than others, but 
less suitable for longitudinal monitoring because of lower precision. 
Thus, the femoral neck may be more suitable for initial 
measurement than the spine because it is not liable to interference 
by degenerative changes that may affect the spine. However, for 
sequential measurements, the spine may be more valuable because 
of its greater precision and response to therapy. The forearm has 
the advantage of precision but may change less than the spine and 
may be less predictive of fracture (particularly hip fracture), than 
the proximal end of the femur. On the other hand, the forearm 
reflects overall peripheral fracture risk more closely than the spine. 
It must also be realized that spinal densitometry cannot usefully be 
applied to crushed vertebrae, nor is forearm densitometry of 
diagnostic value at a fracture wrist. Therefore, at present it is 
premature to lay down firm guidance as to choice of measurement 
site. 
 
 
2.4.4 Interpretation 
 
The results of the DEXA scan are scored (Table 2.1) in comparison 
with the BMD of young, healthy individuals, resulting in a 
measurement called a T-score. A T-score of –2.5 or lower, is 
considered to be osteoporosis and therefore indicates a high risk of 
fracture (Nordin, 1994). T-scores between –0.1 and –2.5 are  
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generally considered to show osteopenia. The risk of fractures is 
generally lower in people with osteopenia than in those with 
osteoporosis, but if bone loss continues, the risk of fracture 
increases. 
 
Men and women with BMD values of 2.5 standard deviations or 
more below the average for a young healthy population (i.e. 
osteoporosis), should be offered appropriate intervention. 
Intervention can also be offered to individuals with osteopenia who 
have strong risk factors that increase their risk of fracture. 
 
 
TABLE 2.1 World Health Organization Classification of Osteoporosis (Kanis, 
1994) 
Definition   Criteria 
Normal a value for BMD or BMC within 1 SD of the young 
adult reference mean 
Low bone mass a BMD or BMC value of more than 1 SD, but less 
than 2.5 SD below the young adult mean 
Osteoporosis BMD or BMC more than 2.5 SD below the young adult 
mean 
Severe osteoporosis BMD or BMC more than 2.5 SD below the young adult 
mean plus one or more fragility fractures 
 
BMD = Bone Mineral Density; BMC = Bone Mineral Content; SD = Standard Deviation 
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2.5 RISK FACTORS for fractures 
 
At greatest risk for osteoporosis are postmenopausal (including 
early or surgically induced menopause) white and Asian women 
who are thin or small and have a positive family history of the 
disease (Kanis, 1994). While women are more likely than men to 
develop the disease, all men also suffer from osteoporosis. 
 
“Lifestyle” factors that enhance the likelihood of osteoporosis 
include smoking cigarettes, abusing alcohol, being sedentary, and 
consuming too little calcium. Genetic factors however, are also 
important determinants of peak bone mass (Amin, 2004).  
 
Vitamin D deficiency may contribute to fracture risk in the elderly 
and premature menopause (surgical or non-surgical) hastens the 
appearance of osteoporosis (Christiansen, 1993). Estrogen 
deficiency in premenopausal women, caused, for example, by 
anorexia nervosa, excessive exercise, and hyperprolactinemia, 
induce bone loss and may reduce peak bone mass.  
 
Osteoporosis can stem from diseases such as multiple myeloma, 
severe primary hyperparathyroidism, and hyperthyroidism, from 
exposure to certain drugs such as glucocorticoids (Figure 2.4) in 
excess and gonadotropin-releasing hormone agonists and 
antagonists, and from surgical procedures such as gastrectomy 
(secondary osteoporosis) (Amin, 2004). Anyone who needs to take 
glucocorticoid medications for more than 3 months is at risk of 
developing osteoporosis and fractures. Glucocorticoid medications  
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have both direct and indirect effects on bone tissue that lead to 
bone loss. These medications can directly affect bone cells, and 
thereby slow the rate of bone formation. In addition, the 
medication can interfere with the body’s handling of calcium and 
affect levels of sex hormones, leading to increased bone loss. The 
risk factor for these patients is especially high, if other major risk 
factors are present as well (Amin, 2004). 
 
 
 
 
FIGURE 2.4 Probable sites of glucocorticoid effects on calcium 
metabolism in man and the mechanisms by which these changes produce 
either bone formation or increased bone resorption (Riggs and Melton, 
1995). 
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Thyroid hormone replacement associated with sub-clinical or clinical 
hyperthyroidism is also a cause of bone loss (Amin, 2004).  
 
Osteoporosis occurring in middle-aged and elderly men is commonly 
associated with alcohol abuse, smoking, immobilization, 
hypogonadism and medications. Low testosterone levels can also be 
a cause (Fujiwara, 2006). It is, however, possible with the coming 
of, an aged society, that male patients with osteoporosis are 
increasing, and it is also important to prevent the disease and treat 
them (Fukunaga et al., 2006). 
 
Falls are essential precipitating events in hip and other types of 
osteoporotic fractures. Contributing to the risk of falls are many 
factors that reduce balance in the elderly, including the effect of 
aging per se, diseases, and drugs (Christiansen, 1993). 
 
According to the National Osteoporosis Foundation of South Africa, 
osteoporosis is less common in our Black populations, but unlike 
the situation in Europe and America, the lumbar bone mass of Black 
and White South Africans is nearly identical (National Osteoporosis 
Foundation of South Africa, 2004). The paucity of accurate local 
statistics on the incidence of osteoporosis and related fractures is a 
major stumbling block in the drive to prevent and manage the 
disease optimally. The migration of especially the black population 
from rural areas to the cities in search of work and an improved life 
will have further implications on their bone health – the nature of 
which is uncertain and constitutes an important research topic. In 
South Africa, where malnutrit ion and infections (including the  
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HIV/AIDS pandemic and tuberculosis) are rife; osteoporosis is not  
regarded as a health priority. Access to diagnosis and treatment is 
not available to a large section of the population. In state hospitals, 
the availability of modern drugs to manage osteoporosis is limited 
because of high costs (National Osteoporosis Foundation of South 
Africa, 2003). 
 
 
2.6 METHOD OF MEASURING 
 
Bone is one of the most difficult organs to study and osteoporosis 
is one of the most common problems of the elderly (Cameron et al., 
1999). Until very recently osteoporosis was difficult to detect unt il a 
patient presented with a broken hip or a crushed vertebra and by 
that time it was too late to use preventative therapy. The strength 
of bone depends to a large extent on the mass of bone mineral 
present, and the most striking feature in osteoporosis is the lower 
than normal bone mineral mass. 
 
A simple technique to measure bone mineral mass in vivo with good 
accuracy and precision (reproducibility) was sought and it was 
hoped that such a technique could be used to diagnose 
osteoporosis before a fracture occurred and also to evaluate 
various types of therapy for osteoporosis (Cameron et al., 1999). 
Since bone mineral mass decreases very slowly, 1 to 2% per year, 
a very precise technique was needed to show changes. 
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Several techniques are available at present, but DEXA is the most 
widely used technique, because of its ability to assess bone mass at  
both axial and appendicular sites, its high reproducibility, and very 
low doses of radiation associated with measurement (Mazess et al., 
1989). DEXA is based on the method of X-ray spectrophotometry 
and was first introduced commercially as the direct successor to 
Dual Photon Absorptiometry (DPA), in 1987. Using the principles of 
DPA, the radionuclide source in DEXA is replaced by an X-ray tube. 
Two distinct energy level beams are either generated by the X-ray 
generator or filtered from an X-ray spectrum (depending on the 
manufacturer). The main advantages of an X-ray system over a 
DPA radionuclide system are the shortened examination time due to 
an increased photon flux of the X-ray and the greater accuracy and 
precision due to higher resolution and the lack of radionuclide 
decay. DEXA has taken the place of DPA, thereby reaching great 
acceptance in clinical medicine and research. 
 
Two X-ray beams with different energy levels are aimed at the 
patient’s bones. When soft tissue absorption is subtracted, the BMD 
can be determined from the absorption of each beam by bone. 
Even if DEXA uses X-rays to assess BMD, the radiation doses is 
approximately 1/30th that of a standard chest X-ray (Cameron et 
al., 1999) 
 
The preferred anatomic sites for DEXA measurement of BMD 
include the lumbar spine, proximal femur and whole body, but 
other parts, such as the forearm and calcaneus, can also be 
scanned. 
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The digital image resulting from the measurement allows a gross 
survey of the region examined. The sophisticated software of all 
DEXA devices allows one to identify regions of interest with distinct 
compositions of trabecular and cortical bone such as the femoral 
neck and Ward’s triangle, and the ultradistal or the distal third of 
the radius. Additionally, fractured vertebrae may be excluded from 
analysis. 
 
DEXA has a reported precision (reproducibility) in research studies 
of about 1.0 – 1.5 % at the spine and about 3% at the proximal 
femur (Jergas and Genant, 1993).  
 
Bone densitometry is useful in diagnosing osteoporosis, in 
predicting fractures and also in monitoring the patient’s response to 
treatment.  
 
Postmenopausal women lose bone at a rate of approximately 1-2% 
per year; therefore biennial scans are generally adequate (Amin, 
2004). In patients who are likely to have increased bone loss (e.g 
glucocortiocoid treatment), more frequent scans may be indicated. 
The examination procedure takes up to 10 minutes. 
 
 
2.7 SOCIO-ECONOMIC aspects 
 
The social burden of osteoporosis varies with the incidence of 
fractures. Fracture rates vary markedly in different countries, being 
highest in North America and Europe, particularly in Scandinavia  
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(Bacon, 1996). The risk of osteoporotic fractures is lower in Africa 
and Asia, but worldwide projections show that it will probably 
increase markedly in the future (Gullberg et al., 1997). 
Approximately 10 million people are at risk of suffering from 
osteoporosis in South Africa (National Osteoporosis Foundation of 
South Africa, 2004). 
 
Osteoporosis and the fractures associated with it constitute a major 
public health concern (Johnell, 1997). Hip fractures account for 
significant morbidity, disability, decreased quality of life and 
mortality. The adverse effects of vertebral and forearm fractures on 
most of the activities of daily living are also significant, although 
not as great as those of hip fracture. The cost of care is high and 
the implications for public health expenditure are serious. In both 
developed and developing countries, osteoporosis will become a 
major burden as the population ages. 
 
Socio-economic evaluation of osteoporosis can be undertaken to 
estimate the cost of the disease, the effectiveness of treatments 
and the effects of strategies to identify patients at high risk, such 
as screening and case-finding, or to assess global strategies (World 
Health Organization, 2003). The costs of osteoporosis can be 
divided into direct (fracture-related) and indirect costs. The indirect 
costs depend on a number of assumptions, and in particular on the 
impact of working definitions of osteoporosis based on bone density 
threshold and on indices of vertebral fractures. The indirect costs of 
osteoporosis require further investigation. The costs of osteoporosis 
are considerable and are comparable with those of many other  
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chronic disorders in women, including breast cancer, arthritis, 
diabetes and chronic obstructive pulmonary disease. Hip fractures 
account for more than half of all direct costs. 
 
The total cost of osteoporosis is difficult to calculate because it 
includes the costs of acute hospital care, loss of working days for 
family carers, long-term care and medication. Cost estimates are 
based on many assumptions, making cost comparisons between 
countries difficult, if not impossible (World Health Organization, 
2003). 
 
Up to 20% of victims of hip fracture die within 1 year and fewer 
than 50% ever regain the functional capability to lead an 
independent life. The cost of acute fracture care in the USA 
exceeded $10 billion in 1990. Early intervention has been shown to 
reduce the rate of vertebral and hip fractures by 50-70% (World 
Health Organization, 2003). 
 
Osteoporotic fractures in white, Asian and “mixed race” populations 
in this country are similar to those reported from North America 
and Europe. South African blacks, however, have the lowest hip 
fracture prevalence in the world. No data on the incidence of 
vertebral fractures in this country have been published and the cost 
of fracture care and also of selected screening has not been 
measured (National Osteoporosis Foundation of South Africa, 
2004). 
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Hip fractures are a burden to both the individual and the 
community and only 50% of patients ever regain the mobility and  
 
independence they enjoyed 12 months before the hip fracture 
occurred (Hansen et al., 1991). In 1997 Johnell predicted that the 
number of hip fractures worldwide is projected to increase from 1.7 
million in 1990 to 6.3 million in 2050 because of the aging of the 
population; therefore, based on the currency values and a cost of 
$21 000, 00 per patient the total cost of hip fractures by the year 
2050 will be $131.5 billion (Johnell, 1997). 
 
The personal and social costs of osteoporosis and its complications 
in the Western world are enormous and will continue to rise if no 
measures are taken (Hansen et al., 1991). 
 
 
2.8 PREVENTION and TREATMENT 
 
Ideally, osteoporosis is a condition that should be prevented from 
occurring, but this is unrealistic given our present state of 
knowledge and ability to influence it. At best building strong bones 
during childhood and adolescence can be the best defense against 
osteoporosis developing later. 
 
Treating established osteoporosis is difficult, expensive and often 
disappointing (Canadian consensus on osteoporosis, 2003). It is 
therefore essential to be able to prevent the disease from 
developing or to treat the early stage of the disease before  
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fractures occur. Prevention could be accomplished by treating all 
women. But the drugs available for prevention of osteoporosis may 
have long-term adverse effects and are often expensive. 
The goal of osteoporosis management must be to prevent fracture 
(Jaglal et al., 2000). 
 
To prevent osteoporotic fractures, individuals at risk of fractures  
must first be identified, and then the appropriate interventions to 
reduce this risk, such as life style modifications and hormone or 
other drug therapies, must be implemented (Jaglal et al., 2000). 
Preventative measures aim to stimulate bone formation and to 
reduce excessive bone loss. 
 
The following health style measures can help to maintain healthy 
bones (Amin, 2004): 
 A balanced diet, rich in calcium and diary products; calcium 
supplements; 
 Regular exercise, preferably weight-bearing; Bone is living 
tissue and, like muscles, bones should be used regularly or 
they will deteriorate; 
 Maintenance of eugonadism (in women until age 45-50 
years); 
 Cessation of smoking; 
 Decrease in alcohol intake; 
 The avoidance of bone toxic agents; 
 Promotion of vitamin D supplementation and/or adequate 
time spent outdoors in the case of the elderly; 
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 Programs aimed at preventing falls among the elderly, and 
use of hip protectors in those at great risk of falls;  
 Calcium supplements. 
 
Pharmacological interventions for which there is consistent 
evidence from randomized controlled trials of antifracture efficacy, 
include supplementation with calcium and vitamin D in the elderly, 
and treatment with bisphosphonates in postmenopausal women 
with osteoporosis (Amin, 2004). Selective estrogen receptor 
modulators also prevent vertebral fractures. In general, 
pharmacological interventions are expensive and may have adverse 
effects. To be most cost-effective, they should therefore be 
targeted at those at highest risk of fracture. Current ability to 
predict fractures means that intervention is possible before fracture 
has occurred. It is, however, never too late to intervene in patients 
with osteoporosis. Bone loss from glucocorticoid treatment can also 
be decreased if the patient uses calcium and vitamin D supplements 
(Amin, 2004). 
 
Osteoporosis poses a problem to clinicians. On the one hand, when 
bone mass has decreased substantially and fractures occur, 
osteoporosis is easy to diagnose but difficult, if not impossible, to 
treat (Hansen et al., 1991). Any substantial reduction in these costs 
depends on preventing fractures rather than improving the 
treatment of patients with fractures, and once bone mass has 
decreased to the point where fractures begin to occur, therapeutic 
options are limited. Generally accepted treatments for osteoporosis 
reduce bone resorption; however, these agents may maintain  
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existing bone mass but cannot increase it substantially. As a 
consequence, interest has shifted from treating patients with 
fractures to preventing fractures by preserving bone mass (Melton 
et al., 1990). 
Because most bone treatments do little more than prevent further 
bone loss, prevention of osteoporosis before it develops is clearly 
the desirable ideal (Nordin, 1994). 
 
 
2.9 FUTURE IMPLICATIONS 
 
Until recently, osteoporosis was an under-recognized disease and 
considered an inevitable consequence of aging (World Health 
Organization, 2003). Perceptions have changed, as epidemiological 
studies have highlighted the high burden of the disease and its 
costs to society and health care systems. 
 
Osteoporosis affects an estimated 75 million people worldwide since 
both world population and life expectancy are increasing, and this 
figure is expected to increase by 310% in men and 240% in women 
by the year 2050 (International Osteoporosis Foundation, 2005). 
 
Preventative strategy will therefore need to be developed and 
implemented. Family physicians can help with early diagnosis and 
intervention and should discuss lifestyle modification with patients 
(Khan, 2003). 
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In addition to education for physicians, an important theme is the 
need for patient education. A study by Tellier et al highlights the 
importance of educating patients as well as physicians to increase 
awareness (Tellier et al., 2001). 
 
Proper diagnosis and management of osteoporosis minimize injury 
and disability, improve quality of life for patients and reduce cost to  
society. Rationally targeted methods of screening and diagnosis are 
safe and cost effective. Harmful side effects and costs of 
recommended therapies are minimal compared to the harm and 
costs of untreated osteoporosis (Scientific Advisory Board, 
Osteoporosis Society of Canada, 1996). 
 
The availability of highly active anti-retroviral therapy to treat 
patients suffering from AIDS, and the metabolic side effects of this 
therapy, including its effects on bone, is becoming relevant, 
according to the National Osteoporosis Foundation of South Africa 
(National Osteoporosis Foundation of South Africa, 2003).  
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3.1 STUDY DESIGN 
 
This is an analytical study that examines the influence of a low BMD 
result on the treatment of patients classified with either osteopenia 
or osteoporosis. 
 
 
3.2 STUDY SITE 
 
The research study was conducted at Universitas Academic 
Hospital. All the patients were referred by physicians in 
Bloemfontein, except for 5 patients who were referred by General 
Practitioners from the rural areas of the Free State. 
 
 
3.3 STUDY POPULATION 
 
3.3.1  Number of subjects 
 
A total of 50 patients were included. Patients were recruited 
between January 2004 and November 2004. Patients who complied 
with the inclusion criteria and also gave their consent (Appendix B) 
were enrolled. 
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3.3.2  Inclusion criteria 
 
Patients were included in the study when classified as having 
osteopenia or osteoporosis according to the WHO criteria (Table 
2.1, p18) and: 
 Belonged to any population group 
 Were aged between ages 18-80 years 
 Were of either sex 
 Had a telephone 
 Were prepared to give consent 
 
3.3.3  Exclusion criteria 
 
 Refuse to participate 
 Not classified as having either osteopenia or 
osteoporosis  
 No telephone 
 
3.3.4  Justification for inclusion and exclusion criteria 
 
The patient had to give consent before they could be enrolled in 
the study. This was for ethical and confidential reasons. 
 
To be representative the inclusion criteria included osteopenic or 
osteoporotic patients from any population group. 
 
The patient had to have access to a telephone in order for us to 
contact him/her after the 2-month period. 
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3.3.5  Subject identification 
 
For identification within the study, the patient files were numbered 
starting with 01. The numeric value was used for the study to 
ensure the confidentiality of the patient. 
 
3.3.6  Withdrawal 
 
Participation was voluntary and patients could withdraw from the 
project at any stage without any fear that it would be held against 
them. 
 
3.3.7  Financial implications for patients 
 
The financial implications were minimal, as the patients were 
already booked for a routine DEXA. The patients received no 
remuneration for their participation. 
 
 
3.4 MEASUREMENT TECHNIQUES, APPARATUS AND FORMS 
 
3.4.1  Pre-study screening 
 
 Patients were booked for a routine DEXA scan. 
 The nature of the research project was discussed with 
the patient. 
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 If the patient agreed on participation, a written 
consent was given (Appendix B). 
 The patient and his/her data were weighed against the 
inclusion and exclusion criteria. 
 
 3.4.2  Method of data collection and data analysis 
 
After patient consent was obtained, he/she completed a 
questionnaire (Appendix A). Data on family history, medical history 
and lifestyle were obtained. After a 2-month period another 
questionnaire (Appendix C) was completed by telephone. This 
follow-up questionnaire collected information on the feedback 
received from the physician. 
 
3.4.3  Apparatus 
 
The gold standard for quantifying BMD is currently DEXA, which 
offers the advantages of precision and low radiation doses.  
 
DEXA measures the transmission of X-rays of 2 different photon 
energies through the body, allowing for the measurement of bone 
and soft tissue mass (Jergas and Genant, 1993). It has a reported 
precision (reproducibility) in research studies of about 1.0 – 1.5% at 
the spine and about 3% at the proximal femur. 
 
Bone scans were performed on the HOLOGIC 4500 QDR, a multiple 
detector, fan beam, Dual Energy X-ray Densitometer (Figure 3.1).  
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The Hologic 4500 QDR Bone Densitometer estimates the Bone 
Mineral Content (BMC) in grams, and the BMD in grams per cm2. The 
QDR 4500 uses a low level of X-rays with two different energies to 
estimate BMC and BMD. The radiation exposure at a distance of two 
metres from the equipment is less than one mR/hour. 
 
The two main components of the HOLOGIC QDR 4500, are 1) the 
Examination Table Unit (examination table with mattress; mechanical 
drives to move the table and C-arm; a safety switch, and an 
operator’s control panel) and 2) the C-arm (X-ray source and 
detector; mechanical drive to rotate C-arm; laser cross-hair indicator 
for patient positioning), as is illustrated in Figure 3.1.  
 
 
 
FIGURE 3.1 Hologic QDR 4500 bone densitometer (Hologic Instructor’s Manual, 
1996). 
 Chapter 3                                                                                                                      p 39 
 
 
3.4.4  MEASUREMENT TECHNIQUES 
 
Procedure 
 All DEXA scans were performed on a Hologic 4500QDR, 
provided and maintained by The Scientific Group. 
 After the patient’s demographic data was entered into 
the computer, the test procedure was thoroughly 
explained to the patient. 
 Before the patient got onto the examination table, all 
metal (snaps, zippers, belts, jewelry, buttons, etc.) in 
the scan area were removed. 
 If the patient had had an X-ray exam with Contrast 
Medium or a Nuclear Medicine Isotope study within 7 
days prior to the bone densitometry, the scan was 
postponed until seven days after the procedure had 
been done. 
 If there was any chance that the patient might be 
pregnant, the scan was postponed until pregnancy was 
ruled out. 
 Scans of the left or right hip and the lumbar spine were 
performed within a designated scan area on the 
examination table of a Hologic 4500 QDR. 
 Special positioning aids for the spine and hip scan, 
aided in positioning of the patient, and also ensured 
consistent positioning for follow-up scans. 
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 DEXA uses X-rays to assess bone mineral density, 
however, under standard operating conditions; the 
entrance dose to the patient is less than 35 mR, which 
is approximately the same exposure as a standard 
chest X-ray. 
 After the necessary explanation and preparation, the 
patient was positioned on the bed (Figure 3.2), with 
the help of positioning aids and a laser beam guide. 
 The C-arm was positioned correctly over the region of 
interest (e.g., Hip or Lumbar Spine) before the 
scanning procedure could begin. 
 The estimated time for both scans was 10 minutes. 
 The procedure itself is painless with no discomfort for 
the patient, except for lying motionless for the period 
of the scan. 
 Each patient received a standard scan procedure that 
consisted of both the spine and the left or right hip 
(see Figures 3.3 and 3.4). 
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FIGURE 3.2 Patient positioning during scan procedure (Hologic 
Instructor’s Manual,1996).
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FIGURE 3.3 Example of analysed left hip 
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FIGURE 3.4 Example of analysed lumbar spine 
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3.4.5  Quality control 
 
Quality control is performed daily on the Hologic 4500 QDR 
according to the manufacturer’s specifications. This is to verify that 
the Hologic 4500 QDR is performing properly and also to ensure 
accuracy and reliability. 
 
3.4.6  Data sheet 
 
Data of analyzed BMD scans were entered on a patient data sheet 
before the processing thereof (Appendix D). 
 
 
3.5  STATISTICAL ANALYSIS 
 
Data were processed, interpreted and sent back to the referring 
physician. Data from patients that were classified as either 
osteopenic or osteoporotic, according to the results obtained from 
the Bone Densitometry, were used. 
 
Bone Density values are expressed in relation to reference data as 
standard deviation scores: a Z-score representing the number of 
standard deviations above or below the age and sex matched mean 
reference value, and a T-score similarly expressed in relation to 
reference values for young adults (Compston et al., 1995). 
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Osteopenia is defined as a T-score between -1 and -2.5 and may 
constitute an indication for prophylaxis, depending on the age of 
the woman and the risks and benefits of the proposed treatment.  
 
Osteoporosis is defined as a T-score below -2.5 and includes nearly 
all women who will sustain a fragility fracture. It can be regarded 
as an absolute indication for intervention. 
 
A statistical analyst from the Department of Biostatistics, University 
of the Free State, was consulted for assistance with the processing 
of data. 
 
 
3.6 ETHICS 
 
3.6.1  Ethical approval 
 
The study protocol and the informed consent used in the study 
were submitted to the Ethical Committee of the University of the 
Free State and approval was obtained prior to the start of the study 
(ETOVS NR 121/03). 
 
3.6.2  Subject information and informed consent 
 
All the patients were informed at the time of the DEXA about the 
purpose of the research project, after which they signed the 
informed consent form (Appendix B). Both the information and the 
consent form were available in English, Afrikaans and South-Sotho. 
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3.6.3  Safety variables 
 
The study posed no hazard to the participants and as the patients 
were referred for a routine Bone Densitometry, the study itself had 
no adverse effects on the patient. 
 
3.6.4  Premature Discontinuation of study 
 
It did not become necessary to discontinue the study prematurely 
and at no stage during the course of the research did the 
researcher or the study leaders feel that any patient’s 
confidentiality was compromised or that any unethical procedures 
had occurred. 
 
3.6.5  Good Clinical Practice (GCP)/Quality assurance 
 
All the clinical work conducted under this protocol was subjected to 
GCP guidelines. 
 
The declaration of Helsinki's basic principle number 3 states that 
research should be conducted only by scientifically qualified people 
and under the supervision of adequately qualified people.  
 
The study was conducted in accordance with the good clinical 
practice guidelines (GCP) and the declaration of Helsinki (World 
Medical Association Declaration of Helsinki, 2002). 
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3.6.6  Confidentiality 
 
The confidentiality of this study was of utmost importance and at 
no time during the research was any of the patients' identification 
made known to any people other than those to whom the patient 
had given his/her consent. 
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4.1 GENERAL 
 
A total of 50 patients was included in the research project after the 
exclusion and inclusion criteria had been met. Only patients who 
were classified as having osteopenia or osteoporosis, according to 
the WHO criteria (Table 2.1, p18), were included in the study. This 
study adhered to these classifications. 
 
During the initial planning of this study 200 patients were planned 
for, however, due to staff shortage and extra workload, only 50 
patients were recruited for the study. Patients were referred by 
Universitas Academic Hospital as well as by other points of care 
(Figure 4.1). 
 
 
FIGURE 4.1 Proportion of patients referred from UAH and other 
points of care. 
36%
64%
Universitas Other points of care
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The data used in this study were collected from January 2004 up to 
November 2004. Physicians from Universitas Academic Hospital 
(UAH) referred 32 patients (64%) and 18 patients (36%) were 
referred from other points of care (Figure 4.1). All the patients 
were referred by physicians in Bloemfontein, except for 5 patients 
who were referred by general practitioners from the rural areas of 
the Free State. The distribution from the other points of care can 
be seen in Figure 4.2. 
 
 
 
 
 
FIGURE 4.2 Source of patients referred for BMD measurements 
from other points of care. 
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From UAH most patients were referred by the Endocrinology Clinic 
(Figure 4.3).  
 
 
3%
16%
6%
6%
6% 3% 3% 13%
44%
Neurology Gastro-enterology
Endocrinology Oncology
Orthopedic Pain Clinic
Arthrits Pulmonology
Internal Medicine/Geriatric
 
 
FIGURE 4.3 Source of referral of patients for BMD measurements from 
UAH. 
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Indications for the referral of the patients for a DEXA scan were 
very vague and differ greatly. In Table 4.1 the various indications 
for a DEXA scan, are summarized. 
 
 
 
TABLE 4.1 Summary of the indications for DEXA as on the request 
forms. 
 
INDICATION  Number of patients 
Routine examination 20(40%) 
? Osteoporosis 10(20%) 
X-rays show osteoporosis 4(8%) 
Patient on cancer treatment 4(8%) 
Just ask for DEXA 2(4%) 
Back pain 4(8%) 
Family history 2(4%) 
Pains in hips and knees 1(2%) 
Previous fracture 1(2%) 
Glucocorticoids use 2(4%) 
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4.2 PATIENT POPULATION 
 
Forty-nine of the patients in the study population were female (Table 4.2, 
p50). Their ages ranged between 14 – 86 years of age (average age was 
57,2 years). Most patients were between 40 and 70 years old. A small 
number (8%) of the patients were under the age of 40 years. Ten 
patients (20%) were between 40 and 50 years; fifteen patients (30%) 
between 50 and 60, and eleven patients (22%) above 60 years (Figure 
4.4). 
 
 
4%
20%
30%
22%
14%
6% 2% 2%
10-20 yrs 20-30 yrs 30-40 yrs 40-50 yrs 50-60 yrs 60-70 yrs
70-80 yrs 80-90 yrs
 
FIGURE 4.4 Age distribution of study population. 
 
 TABLE 4.2 Summary of patient data. (F-Female; M-Male; BMI-Body Mass Index; SD-standard deviation) 
PATIENT 
NUMBER 
GENDER AGE Weight (kg) Height (cm) BMI RESULTS 
1 F 29 47 156 19 OSTEOPENIA 
2 F 61 45 159 18 OSTEOPOROSIS 
3 F 48 50 157 20 OSTEOPOROSIS 
4 F 78 50 148 23 OSTEOPOROSIS 
5 F 47 75 176 24 OSTEOPENIA 
6 F 81 88 157 36 OSTEOPENIA 
7 F 86 53 162 20 OSTEOPOROSIS 
8 F 57 72 162 27 OSTEOPENIA 
9 F 79 74 165 27 OSTEOPENIA 
10 F 35 55 169 19 OSTEOPENIA 
11 F 62 43 150 19 OSTEOPOROSIS 
12 F 41 73 162 28 OSTEOPENIA 
13 F 56 52 152 23 OSTEOPOROSIS 
14 F 58 62 165 23 OSTEOPOROSIS 
15 F 62 80 160 31 OSTEOPOROSIS 
16 F 69 88 157 36 OSTEOPENIA 
17 F 48 79 165 29 OSTEOPENIA 
18 F 55 67 160 26 OSTEOPENIA 
19 F 64 59 155 25 OSTEOPENIA 
20 F 47 72 160 28 OSTEOPENIA 
21 F 73 56 159 22 OSTEOPENIA 
22 F 31 64 172 21 OSTEOPOROSIS 
23 F 70 56 149 25 OSTEOPENIA 
24 F 50 59 166 21 OSTEOPOROSIS 
25 F 41 86 160 34 OSTEOPENIA 
26 F 66 55 164 20 OSTEOPENIA 
27 F 42 64 172 21 OSTEOPENIA 
28 F 49 44 158 18 OSTEOPOROSIS 
29 F 65 96 160 38 OSTEOPOROSIS 
30 F 56 68 169 24 OSTEOPOROSIS 
31 F 48 57 160 22 OSTEOPENIA 
32 F 14 48 162 18 OSTEOPOROSIS 
33 F 66 84 158 34 OSTEOPENIA 
34 F 56 65 166 24 OSTEOPENIA 
35 F 70 71 161 27 OSTEOPENIA 
36 F 50 64 152 28 OSTEOPOROSIS 
37 F 76 66 159 26 OSTEOPOROSIS 
38 F 58 70 152 30 OSTEOPENIA 
39 F 63 82 165 30 OSTEOPENIA 
40 F 41 61 165 22 OSTEOPENIA 
41 F 54 52 154 22 OSTEOPENIA 
42 F 53 50 170 17 OSTEOPOROSIS 
43 F 58 68 165 25 OSTEOPENIA 
44 F 59 90 159 36 OSTEOPENIA 
45 F 61 65 162 25 OSTEOPENIA 
46 F 54 97 172 32 OSTEOPENIA 
47 M 53 78 171 27 OSTEOPENIA 
48 F 77 70 153 30 OSTEOPENIA 
49 F 62 52 153 22 OSTEOPOROSIS 
50 F 81 55 158 22 OSTEOPOROSIS 
AVERAGE (n=50)  57.2 65.5 161   
SD   14 6   
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Table 4.2 also shows the clinical characteristics and demographic 
data of the study population. This includes the height, weight and 
Body Mass Index. 
 
The Body Mass Index (BMI) for each patient was calculated using 
the following formula, and classified according to Table 4.3:  
BMI = weight (kg)/height2(m) 
 
 
TABLE 4.3 The following classification of BMI was used in the 
study (WHO, 2000). 
Underweight A value less than 17.9 
Normal A value of 18 to 25 
Overweight A value of 25.1 – 29.9 
Obese (moderate) A value of 30-40 
Obese (severe) A value more than 40 
 
Thirty(60%) patients of the study population had a normal BMI, 
and of these, 15(50%) were osteopenic and 15(50%) osteoporotic 
(Table 4.2). 
 
Nine(18%) patients were classified as being overweight according 
to their BMI, and of these, 7(78%) were osteopenic and 2(22%) 
osteoporotic(Table 4.2). 
 
Eleven (22%) patients were moderately obese, and of these 
9(82%) were osteopenic and 2(18%) osteoporotic(Table 4.2). 
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Only 1 patient was underweight according to her BMI and her BMD 
was in the osteoporotic range (Table 4.2). 
 
 
4.3 PATIENT MEDICAL HISTORY 
 
Illustrated in Table 4.4 are the more relevant medical conditions 
that may pose a risk for osteoporosis in the study population.  
 
TABLE 4.4 Risk factors for osteoporosis in study population 
 
RISK FACTOR NUMBER of PATIENTS 
 
Glucocorticoid use (more than 6 months) 
                      3 osteopenia 
8(16%) 
                      5 osteoporosis 
 
Hormone replacement therapy 
                     13 osteopenia 
18(37%) 
                      5 osteoporosis 
 
Hypothyroidism 
                     13 osteopenia 
17(34%) 
                      4 osteoporosis 
 
Rheumatoid arthritis 
                      9 osteopenia 
14(30%) 
                      5 osteoporosis 
 
Hysterectomy 
                      22 osteopenia 
37(76%) 
                      15 osteoporosis 
 
Diabetes 
                       2 osteopenia 
4(8%) 
                      2 osteoporosis 
 
Early menopause (<45 years) 
                      15 osteopenia 
17(34%) 
                      2 osteoporosis 
 
Smoking history 
                      13 osteopenia 
18(37%) 
                       5 osteoporosis 
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TABLE 4.4(continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

The GIT disturbances include spastic colon, ulcerative colitis, gastritis and Cohn’s disease.  
GIT = Gastro-intestinal tract. 
 
When looking at the number of risk factors (Table 4.4) for each 
patient; 8% of the total patient population had only one risk factor. 
Table 4.5 illustrates that the biggest percentage of patients had two 
risk factors. 
 
TABLE 4.5 Number of risk factors in study population 
 
 
 
 
 
 
 
 
Chronic liver disease 
 
                     2 osteopenia 
2(4%) 
                     0 osteoporosis 
 
Cancer (4 breast, 1 ovarian) 
                     2 osteopenia 
5(10%) 
                     3 osteoporosis 
 
Amenorrhoea (>3 months) 
                     3 osteopenia 
3(6%) 
                     0 osteoporosis 
 
Family history of fractures 
                       2 osteopenia 
5(10%) 
                       3 osteoporosis 
 
≤30 minutes sun exposure 
                      7 osteopenia 
13(26%) 
                      6 osteoporosis 
 
GIT disturbances 
 
                      9 osteopenia 
13(26%) 
                      4 osteoporosis 
NUMBER OF RISK FACTORS PER 
PATIENT 
NUMBER OF PATIENTS 
1 4(8%) 
2 18(36%) 
3 14(28%) 
4 or more 14(28%) 
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When looking at the physical activity of the study population (Figure 
4.5), the following was observed: 
 Twenty-six (52%) of the patients reported levels of physical 
activity of less than 30 minutes of brisk walking per day. 
 Twenty-four (48%) patients had physical activity levels of more 
than 30 minutes of brisk walking per day. 
 
 
The dairy intake of the study population (Figure 4.6) in general, 
showed the following: 
 Four (8%) of the patients reported no dairy intake. 
 Thirteen (26%) patients’ dairy intake was less than 250 ml milk 
per day as they only used milk in their coffee or tea.  
 Thirty-three (66%) patients’ had a dairy intake of 250 ml or 
more per day in the form of cheese, yoghurt and/or milk  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4.5 Patients characterized according to levels of physical activity  
 
 
 
n = 50 
Less than 30 minutes of 
walking per day  
n = 26 (52%) 
 
More than 30 minutes of 
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Osteoporotic 
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Osteopenic 
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Osteoporotic 
n = 13 (54%) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4.6 Patients characterized according to intake of dairy products 
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4.4 BMD RESULTS 
 
 
Out of the 50 patients who had a DEXA scan performed, 31 (62%) 
patients were osteopenic and 19 (38%) had osteoporosis (Figure 
4.7).  
 
 
38%
62%
Osteopenia Osteoporosis
 
FIGURE 4.7 Proportion of patients with BMD in the osteopenic range 
compared to those in the osteoporotic range.  
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Patients were classified according to their T-score (Table 4.6) 
whether they were osteopenic or osteoporotic. This shows the 
following: 
 Of the thirty-two(64%) patients referred from UAH, 17(53%) 
and 15(47%) patients had a BMD in the osteopenic and 
osteoporotic ranges, respectively. 
 Of the 18(36%) patients referred from other points of care, 
14(78%) were osteopenic and 4(22%) osteoporotic. 
 
The final BMD results are explained in Figure 4.8. 
 TABLE 4.6 T-score and Z-score of individual patients. 
 
             T-SCORE                      Z-SCORE 
PATIENT nr Hip Lumbar Hip Lumbar RESULTS 
1 -0.6 -2.2 -0.6 -2.2 OSTEOPENIA 
2 -2.2 -2.5 -1.2 -1.0 OSTEOPOROSIS 
3 -3.3 -4.1 -2.9 -3.4 OSTEOPOROSIS 
4 -2.6 -3.5 -0.6 -0.9 OSTEOPOROSIS 
5 -0.9 -1.3 0.7 -0.1 OSTEOPENIA 
6 0.8 -1.9 0.8 1.2 OSTEOPENIA 
7 -2.9 -2.8 N/A N/A OSTEOPOROSIS 
8 -2.1 -2.4 -0.1 -1.2 OSTEOPENIA 
9 -2.1 -1.6 0.0 1.1 OSTEOPENIA 
10 -2.2 -2.1 -2.1 -2.0 OSTEOPENIA 
11 -2.9 -3.3 -1.8 -1.8 OSTEOPOROSIS 
12 -1.9 -1.5 -1.7 -1.2 OSTEOPENIA 
13 -3.9 -4.5 -3.1 -3.3 OSTEOPOROSIS 
14 -2.2 -3.1 -2.1 -1.8 OSTEOPOROSIS 
15 -1.7 -3.7 -0.6 -2.1 OSTEOPOROSIS 
16 -0.9 -1.6 0.6 0.5 OSTEOPENIA 
17 -1.6 -1.3 -1.2 -0.6 OSTEOPENIA 
18 0.4 -1.5 1.1 -0.4 OSTEOPENIA 
19 -2.4 -1.4 -1.2 0.3 OSTEOPENIA 
20 -1.1 -1.0 -0.7 -0.4 OSTEOPENIA 
21 -1.8 -1.0 -0.1 1.2 OSTEOPENIA 
22 -2.3 -3.3 -1.4 -1.8 OSTEOPOROSIS 
23 -1.2 -2.1 0.3 0.1 OSTEOPENIA 
24 -2.8 -2.1 -2.3 -1.4 OSTEOPOROSIS 
25 -0.4 -1.6 -0.2 -1.3 OSTEOPENIA 
26 -2.2 -1.6 -0.9 0.3 OSTEOPENIA 
27 -1.0 -0.8 -0.8 -0.4 OSTEOPENIA 
28 -2.0 -2.9 -1.5 -2.2 OSTEOPOROSIS 
29 0.4 -2.5 1.7 -0.7 OSTEOPOROSIS 
30 -1.4 -3.2 -1.4 -2.0 OSTEOPOROSIS 
31 -1.4 -1.1 -1.0 -1.0 OSTEOPENIA 
32 -3.5 -3.7 N/A -2.6 OSTEOPOROSIS 
33 -0.9 -2.2 0.4 -0.3 OSTEOPENIA 
34 -2.1 -1.2 -1.3 -0.1 OSTEOPENIA 
35 -1.4 -1.4 0.1 0.1 OSTEOPENIA 
36 -2.2 -2.6 -1.7 -1.8 OSTEOPOROSIS 
37 -1.5 -3.0 -0.2 -0.5 OSTEOPOROSIS 
38 0.0 -1.2 0.8 0.1 OSTEOPENIA 
39 -1.9 -2.3 -0.8 -0.6 OSTEOPENIA 
40 -1.1 -1.1 -0.9 -0.8 OSTEOPENIA 
41 -2.0 -2.4 -1.3 -1.4 OSTEOPENIA 
42 -2.8 -2.2 -2.1 -1.2 OSTEOPOROSIS 
43 -0.6 -1.3 0.3 0.1 OSTEOPENIA 
44 -1.0 -2.1 0.0 -0.7 OSTEOPENIA 
45 -1.5 -1.3 -0.7 -0.5 OSTEOPENIA 
46 -1.1 -2.4 -0.4 -1.3 OSTEOPENIA 
47 -0.2 -1.7 0.2 -1.2 OSTEOPENIA 
48 -1.9 -0.3 0.0 2.2 OSTEOPENIA 
49 -2.6 -2.9 -1.5 -1.3 OSTEOPOROSIS 
50 -3.2 -3.5 -1.1 -0.8 OSTEOPOROSIS 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4.8 Patients classified according to BMD status.  
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4.5 FEEDBACK OF BMD RESULTS 
 
 
Of the 50 patients who had a DEXA scan, only 39(78%) patients 
received feedback from their physician. The remaining 11(22%) 
patients had not received feedback two months after the BMD 
scan was performed. Of these eleven patients, four patients had 
a BMD in the osteoporotic range (Table 4.7). 
 
After their results was discussed with them, 41% of the patients 
made changes in their lifestyle (increased exercise level) and 
21% increased their diary intake. 
 
Thirty-one (79%) patients did receive medication as intervention. 
Two patients did not used their prescribed medication 
 
 TABLE 4.7 Characteristics of patients according to feedback status.  
 
      Patients who received   Patients who did not 
       feedback         receive feedback 
       n = 39 (78%)     n = 11(22%) 
 
Referred from UAH    29(91%)      3(9%) 
Referred outside UAH    10(56%)      8(44%) 
 
BMD in osteopenic range   24(62%)      7(64%) 
BMD in osteoporotic range   15(38%)      4(36%) 
 
Patients offered medication as intervention 31(79%) 
Patients offered no medication   8(21%) 
 
Lifestyle changes: 
↑Physical activity     16(41%) 
↑Dairy intake     8(21%) 
 
Medication prescribed but not using it 2(5%) 
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5.1 INTRODUCTION 
  
The aim of the study was to examine communication between 
referring physicians and patients who had been referred for a DEXA 
scan. 
 
Osteoporosis is a progressive skeletal disease and it causes a 
reduction in bone mass and the consequent risk of a fracture and is 
one of the most destructive diseases in the world. 
 
In South Africa osteoporosis is not regarded as a health priority due 
to malnutrition and infections such as HIV/AIDS and tuberculosis. 
Access to treatment and care is also a problem for most of the 
population, and in State Hospitals the availability of drugs to treat 
osteoporosis is limited due to the high costs (National Osteoporosis 
Foundation of South Africa, 2003). 
  
Nevertheless, osteoporosis remains a disease for which prevention 
is much better than treatment (Drife, 1990) and identifying 
individuals at risk of fracture is a strategy that must be put into 
practice. Ultimately it will be more cost effective than the treatment 
itself. 
 
Interest in osteoporosis has increased, but unfortunately, ignorance 
of this disease is still common among health professionals, patients 
and the public. The family physician plays an important role in the 
prevention of osteoporotic fractures. 
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The implementation of educational programs on osteoporosis can 
prove beneficial to both the patient and the physician.  
 
 
5.2 DISCUSSION 
 
A total of fifty patients was included in the study group. This was 
much smaller than was anticipated but due to staff shortages and 
the inclusion/exclusion criteria, it was just not feasible. Not all the 
patients referred for a DEXA scan had the required low BMD. The 
ideal would have been a much bigger sample group for a bigger 
representation of the population (Table 4.2). 
 
The age distribution of the study group (Figure 4.4) ranged 
between 14 and 84 years (average age was 57,2 years). In spite of 
the small sampling size the study population’s ages were 
representative of most of the age groups. Most patients (25, 50 %) 
were between 40 and 60 years of age. Twenty-one patients (42 %) 
were above 60 years of age. This can be a coincidence or as was 
noted in a study done by Jaglal et al. in 2003, it could be that 
elderly women were less likely to be referred for DEXA. Fifty-two 
percent of their patients were between 45 and 64 years old while 
only 28% were 65 and older. The age group distribution correlates 
well with the data collected for this study. 
 
Also pointed out in the study was that, out of the total of 50 
patients, only one was male (Table 4.2). 
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This can be due to the small patient sample or can support the 
notion that the majority of patients with low BMD are women partly 
because of the hormonal changes that occur at menopause and 
also because of the fact that female patients received more 
attention when it came to low BMD than did male patients. (WHO, 
2003; O’Neill et al., 2004; NOF, 2004; WomensHealthChannel, 
2006). 
 
Another fact that became evident in this study was that the entire 
patient population was Caucasian. Here again it can be contributed 
to the small patient population size or to the fact that black people 
are less likely to have a low BMD than Caucasians. L iterature 
mentions that black people are not affected by osteoporosis as 
frequently as Caucasians (Zizic, 2004). According to the National 
Osteoporosis Foundation of South Africa (2004), osteoporotic 
fractures are less common in our black population. South African 
blacks have the lowest hip fracture prevalence in the world.  
Another factor that could have contributed to the all -Caucasian 
study population is that the few black patients that were sent for a 
BMD did not comply with the inclusion criteria. The race of the 
patient group was, however, not the primary objective of the study.  
 
Concerning the references of the patient population (Figure 4.1), 
Universitas Academic Hospital (UAH) referred more than half of the 
patients (64%). Of these patients, the Endocrinology clinic referred 
the largest number (44%), while the Oncology clinic and Gastro-
enterology referred 16% and 13% respectively (Figure 4.3). 
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The low referral rate from other points of care can be attributed to 
the fact that the service is also available in the Private Hospitals in 
Bloemfontein. The other points of care consisted of specialist 
physicians, general practitioners and 3 Military Hospital (Figure 
4.2). They referred only 36% of the total patient population.  
  
Table 4.1 indicates that 68% of the patients were referred for a 
DEXA scan due to findings during routine examination, direct query 
of osteoporosis, or X-rays indicating osteoporosis. The largest 
number of requests stated Routine DEXA (40%). Fourteen percent 
were more specific concerning the clinical data on the request form, 
e.g. back pain, family history, cancer, prolonged glucocorticoid use 
and previous fracture.  
 
Risk factors for developing osteoporosis (Chapter 2.2.5) include 
hormonal imbalances, genetic factors, modifiable risk factors 
(cigarette smoking, excessive alcohol consumption, high caffeine 
intake, inactive and sedentary lifestyle.), certain medications and 
diseases. In the assessment of the patient populations’ number of 
risk factors (Table 4.4), it was noted that 2 or more risk factors 
(Table 4.5) were present with most of the patients (92%). This 
correlate with the risk factors mentioned in Chapter 2. Ten percent 
of the patient group had a family history of fractures. Sixteen 
percent had a history of glucocortocoid use longer than six months. 
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Lifestyle factors were also present in some of the patients (37% of 
the patients had cigarette smoking history). 
 
Concerning what can be found in the literature, it becomes clear 
that higher levels of leisure time, sports activities, household 
chores and fewer hours of inactivity, were associated with a 
significant reduced risk of a hip fracture (International Osteoporosis 
Foundation, 2005). Physical activity and fitness reduce not only the 
risk of osteoporosis and fracture, but also for fall -related injuries. 
Strengthening the back muscles can also reduce the risk of 
vertebral fractures. 
 
The physical activity levels of the patients in the study population 
were compared to 30 minutes of brisk walking per day. Twenty-four 
(48%) patients reported a high activity level, while 26 (52%) 
patients had a low activity level (Figure 4.5). The findings showed 
that, of the less active group, 23% were osteoporotic. In the 
patient group with high activity levels, 54% were osteoporotic. 
These findings do not concur with the literature where it is stated 
that regular weight bearing exercise can strengthen bone (Amin, 
2004; Jaglal et al., 2000). This may be due to the small patient 
group or as was pointed out by Christiansen, 1993, that excessive 
exercise can cause estrogen deficiency in pre-menopausal women 
with the accompanying risk of a low bone mass. 
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Calcium supplement has been shown to have a positive effect on 
the BMD of postmenopausal women and, together with a Vitamin D 
supplement, it reduces the rate of bone loss and fractures in older  
male and female adults (International Osteoporosis Foundation, 
2005). Lactose intolerance has also been associated with low BMD 
and the increased risk of fracture due to low dairy intake.  
 
The assessment of the dairy intake of the patients showed that 4 
(8%) patients had no dairy intake whatsoever. In this group 75%  
were osteoporotic. Thirteen (26%) patients had a dairy intake of 
less than 250 ml per day, of whom 31% were osteoporotic. The 
high dairy intake group consisted of 33 (66%) patients, of whom 
36% had osteoporosis. 
 
The BMI for each patient was also recorded and compared to the 
BMI classification (Table 4.3). It showed that 30 (60%) of the 
patients had a normal BMI. Of these 30 patients 50% were 
osteoporotic. Nine (18%) patients were overweight according to 
their BMI, and of these patients, 22% were osteoporotic. Eleven 
(22%) patients were moderately obese and only 18% were 
osteoporotic. A Low BMI is also a risk factor for developing 
osteoporosis and the only patient that was underweight, was 
diagnosed with osteoporosis.  
  
After evaluating the results of the patients according to their BMD 
T-score (Table 4.6), 19 (38%) were classified with osteoporosis. Of 
this group, fifteen (47%) patients were referred from UAH and 4 
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 (22%) patients from other points of care (Table 4.8). For these 
patients medical intervention is important. 
For the remaining 31 (62%) osteopenic patients, medical treatment 
would also have been to their benefit.  
 
As the objective of this study is to determine how BMD results 
affect the treatment and management of patients identified with  
either osteopenia or osteoporosis, the emphasis is on 
communication between patient and physician. This is a very 
important aspect as it ensures correct treatment for the patient.  
 
The results of this study showed that 39 patients (78% of the study 
population) did receive their BMD results of which fifteen (38%) 
were osteoporotic (Table 4.7) and in need of treatment. Of the 
22% patients that did not receive feedback, 8% (of the study 
population) were osteoporotic and should have received treatment 
(Table 4.7). 
 
Since various researchers (Christiansen, 1993; Divittorio et al., 
2006; Hough, 2000; Kanis, 1994; Khan, 2003) have consistently 
shown that, depending on the drug and the patient population, 
treatment reduces the risk of vertebral fractures by between 30-
65% and of nonvertebral fractures by between 16-53% 
(International Osteoporosis Foundation, 2005). Should these figures 
be extrapolated to the findings of the present investigation, 
patients that would have responded because of treatment is 4.5-
9.75 patients in the cases for vertebral abnormalities (fractures) 
and 2.4-9.75 patients in the cases for non-vertebral abnormalities  
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 (fractures). The corresponding figures for the patients that did not 
receive feedback that could have benefited according to this notion, 
relates to figures of 1.2-2.6 and 0.64-2.12 respectively.  
 
In this study it became clear that the treatment of choice was 
Alendronate and/or a Calcium supplement (all of which have been 
proven to significantly reduce fracture risk, Diamond, 2002) – 
results pertaining to the choice of treatment not included because 
these finding do not fall within the scope of the aim of the present 
investigation. 
 
The results also showed (Table 4.7) that some of the patients that 
did receive feedback made an effort to improve their lifestyle by 
becoming more active (41%) or by increasing their dairy intake 
(21%). 
 
Fitt et al. (2001) state that an alarming proportion of patients did 
not receive feedback concerning the results of the DEXA and the 
necessary treatment. These findings highlight the fact that patients 
in need of treatment do not always receive it. The same trend (4 
patients from a study population of 50 patients) can be advocated 
for the present findings. 
 
In a study conducted by Jaglal et al. (2003), it was found that 
increasing physicians’ knowledge and educating patients could lead 
to improved management of osteoporosis. Unless physicians 
understand the clinical indications and standards of quality control 
and reporting, there could be potential for overuse and   
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inappropriate use of the DEXA technique (Osteoporosis Society of 
Canada, 1996). The present results suggest trends towards the 
same type of notions if the facts reported in Table 4.7 are 
compared to the facts reported in Table 4.1 for example. 
 
 
5.3 LIMITING FACTORS 
  
Possible limitations identified in the study were: 
1. Small sample size. 
2. Not everybody had telephone access, especially the 
patients from the rural areas of the Free State. 
3. The follow-up data relied solely on the patient’s report, 
and therefore there may have been some inaccuracies 
with respect to their recall of the recommendations. 
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6.1. CONCLUSION 
 
 
    The results of this study showed that: 
 
1. The majority of patients (78% of the study population) receive 
feedback from the referring physician on BMD results indicating 
a significant impact on the management of patients with this 
condition. 
2. The fact that 22% of the study group received no feedback at all 
shows that there is an important lack of communication between 
the physician and the patient. 
3. Communication between physician and patient is a very 
important component in using the information provided by this 
test to its full potential. 
4. The patient’s understanding of osteopenia/osteoporosis, its 
management, and the correct treatment thereof, could be very 
important because for one reason or another, patients were 
prepared to change their life style dynamics.  
5. The physician’s understanding of the results, the interpretation 
and the correct management of a low BMD is also very 
important.  
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The ideal is to identify a low BMD early enough to stop the 
damaging consequences thereof but this is not always feasible due 
to the high costs involved in a DEXA scan. Access to treatment and 
care is also not readily available to a large section of the population 
and, in State Hospitals; the availability of drugs to treat 
osteoporosis is limited due to the high costs (National Osteoporosis 
Foundation of South Africa, 2003). 
 
The life expectancy of females is at present higher than in the past, 
and this higher life expectancy can lead to greater reductions in 
bone mass (O’Neill et al., 2004). Because a disabling fracture can 
be a burden to both the individual and the community, the person 
will still be able to lead a quality life if fractures can be prevented 
(World Health Organization, 2003).  
 
Communication between physicians and patients is a critical 
component in the initiation of therapy for a low BMD. The 
treatment of established osteoporosis and skeletal failure is difficult 
and effective management of this disease involves prevention – 
hence early detection. 
 
 
6.2 RECOMMENDATIONS 
 
Osteoporosis is not part of normal aging although many people 
continue to believe this is true. A comprehensive national effort 
aimed at the prevention, diagnosis and treatment of osteoporosis 
and related fractures is necessary to address this debilitating and  
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costly disease (National Osteoporosis Foundation of America, 
2006). The identification of patients at risk of fracture, prior to 
fracture occurrence, is the ideal (Fitt et al., 2001). A single 
determination of BMD can correctly identify the majority of those at 
risk and DEXA is currently definitely the technique of choice.  
 
An educational plan for patients would be ideal in reducing the 
burden of illness due to osteoporosis. Better education of health 
professionals also ensures that patients receive the most 
appropriate treatment. 
 
A. Basic information that can be to the advantage of a 
patient with a low BMD: 
 Understanding the results of the BMD measurements. 
 Types of treatment available. 
 Diet, exercise, lifestyle, other risk factors. 
 Methods of preventing falls and fractures. 
 
B. This can be accomplished by: 
 Reading books or leaflets, watching videos or listening to 
audiotapes. 
 Attending public meetings or patient support groups to 
learn from other patients with osteoporosis. 
 Reading articles in magazines or newspapers. 
 Watching television programs or listening to the radio.  
 Accessing Web-based information that may be available 
worldwide. 
 Other activities such as World Osteoporosis day. 
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Advanced osteoporosis is difficult to treat and the key to successful 
management thereof is to prevent it (Hough, 2001). Prophylactic 
treatment aiming to optimise bone mass and to prevent loss must 
included a healthy diet, regular exercise, cessation of smoking and 
high alcohol intake. 
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APPENDIX A 
 
Questionnaire completed together with patient 
 VRAELYS 
 
 
PASIëNTINLIGTING 
 
 
 
 
Naam:………………………………………………………………………….………… 
 
Geboortedatum:………………………………………………...……………………… 
 
Ouderdom………………………………Geslag:……………………………………… 
 
Massa:………………………………….Lengte:………………….…………………… 
 
Kontaktelefoonnommer: …………………………………………...………………… 
 
Kontakadres:…………………………………………………………………………… 
 
…………………………………………………………………………………….……… 
 
Verwysende dokter:…………………………………………………………….……… 
 
Adres:…………………………………………………………………………….……… 
 
Indikasie vir aanvraag van toets…………………………………………..………… 
 
Opmerkings:……………………………………………………………………………. 
PT NR. 
 MEDIKASIE 
 
Gebruik u tans of het u in die verlede enige van die volgende middels 
gebruik? 
 
1.  Kortisoon?       Ja   /   Nee 
   
  Naam………………………………………………… 
 
  Daaglikse dosis…………………………………… 
 
  Tydperk?…………………………………………… 
 
______________________________________________________________ 
 
 2. Anti-epileptiese middels?     Ja   /   Nee 
 
  Naam…………………………………………………. 
 
  Daaglikse dosis………………………………………. 
 
  Tydperk?……………………………………………… 
 
______________________________________________________________ 
 
 3. Hormoonvervangingsterapie?    Ja   /   Nee 
 
  Naam…………………………………………………… 
 
  Daaglikse dosis………………………………………… 
 
  Tydperk?………………………………………………. 
 
______________________________________________________________ 
 
4. Antistolmiddels?      Ja   /   Nee 
 
  Naam…………………………………………………… 
 
  Daaglikse dosis……………………………………….… 
 
  Tydperk?………………………………………………… 
 
______________________________________________________________ 
 
 
PT NR 
  
 
 5. Osteoporose medikasie?     Ja   /   Nee 
 
  Naam……………………………………………………… 
 
  Daaglikse dosis…………………………………..………… 
 
  Tydperk?…………………………………………………… 
 
 
 6. Enige ander medikasie?     Ja   /   Nee 
 
  a. Naam……………………………………………… 
 
  Daaglikse dosis…………………………………… 
 
   Tydperk?………………………………………… 
 
 
  b.  Naam……………………………………………… 
 
  Daaglikse dosis…………………………………… 
 
   Tydperk?………………………………………… 
 
 
  c. Naam…………………………………………… 
 
  Daaglikse dosis………………………………… 
 
   Tydperk?………………………………………… 
 
______________________________________________________________ 
 
PT NR 
 GESKIEDENIS VAN SIEKTES 
 
Het u 'n geskiedenis van enige van die volgende siektes? 
 
 1. Longsiektes?      Ja   /   Nee 
 
  Tydperk……………………………………………. 
______________________________________________________________ 
 
 2. Tiroied?       Ja   /   Nee 
 
  Tydperk…………………………………………… 
 
3. Kroniese niersiekte?     Ja   /   Nee 
 
  Tydperk…………………………………………… 
______________________________________________________________ 
 
 4. Diabetes?       Ja   /   Nee 
 
  Tydperk…………………………………………… 
______________________________________________________________ 
 
 5. Osteoporose?      Ja   /   Nee 
 
  Tydperk………………………………………… 
______________________________________________________________ 
 
 6. Rumatoïede artritis?     Ja   /   Nee 
 
  Tydperk………………………………………… 
 
 
 7. Siekte van die Spysverteringstelsel?   Ja   /   Nee 
 
  Tydperk………………………………………… 
______________________________________________________________ 
 
 8. Kroniese lewersiekte?     Ja   /   Nee 
 
  Tydperk………………………………………… 
______________________________________________________________ 
 
 
 
 
PT NR. 
 9. Het u enige ander ernstige siekte gehad? 
bv. 'n siekte waarvoor hospitalisasie nodig was. 
 
 
 Spesifiseer………………………………………………….………………… 
 
 ………………………………………………………………………………… 
 
______________________________________________________________
PT NR. 
 PASIëNT GESKIEDENIS 
 
1. Familiegeskiedenis van fragiliteitsfrakture?   Ja   /   Nee 
  (Vader, moeder, broer, suster) 
 Spesifiseer (indien ja)………………………………………………..……….. 
______________________________________________________________
2.  Rookgeskiedenis       Nooit 
 
Voorheen 
Jare reeds opgehou?…………….…. 
 
          Tans 
 
Hoeveel per dag?…………Hoeveel jare?………………..… 
 
______________________________________________________________ 
 
3. Alkoholgebruik:      geen 
 
         daagliks 
 
        weekliks 
 
      maandeliks of minder 
 
 
4. Fisiese aktiwiteit:Vergelyk met vinnige stap daagliks vir 30 minute  daagliks 
 
         weekliks 
 
         maandeliks 
 
______________________________________________________________ 
 
5. Liggaamsmassa -indeks:………………………………………… 
 
______________________________________________________________ 
 
6. Suiwelinname: vergelyk met 250 ml melk/dag   geen 
 
         daagliks 
 
         weekliks 
 
 Hoeveelheid?……………………………….. 
______________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PT NR. 
 7. < 30 minute sonblootstelling per dag    Ja   /   Nee 
 
______________________________________________________________ 
 
8. Vroeë menopouse (<45 jaar)     Ja   /   Nee 
 
______________________________________________________________ 
 
9. Vorige amenorree (> 3 mnde)     Ja   /   Nee 
 
______________________________________________________________ 
 
10. Histerektomie       Ja   /   Nee 
 
        Jaar…………………….. 
 
       Uterus + eierstokke 
 
        Slegs uterus 
 
______________________________________________________________ 
 
11. Swangerskapgeskiedenis: 
 Hoeveel swangerskappe?………………………… 
 
 Enige miskrame?…………………………..…….. 
 
 Aantal kinders gebore?…………………………… 
 
 Het u geborsvoed? Ja   /   Nee 
 
 Tydperk………………..……………….. 
 
______________________________________________________________ 
 
 
 
 
PT NR 
 QUESTIONNAIRE 
 
 
PATIENT INFORMATION 
 
 
 
 
Name:………………………………………………………………………….………… 
 
Date of birth:………………………………………………...…….…………………… 
 
Age…………………………..…………Gender:……………………………………… 
 
Weight:………………………………….Height:………………….…………………… 
 
Contact number: …………………………………………………...………..………… 
 
Contact address:……………………………………………………………..………… 
 
…………………………………………………………………………………….……… 
 
Referring physician:…………………………………………...……………….……… 
 
Address:…………………………………………..…………….………………………. 
 
Indication for DEXA…………………………………..………………………..……… 
 
 
Remarks:………………………………………………………………...………………
. 
PT NR. 
 MEDICATION 
 
Do you use or did you use any of the following medication? 
 
1. Cortisone?      Y   /   N 
   
  Name………………………………………………………… 
 
  Daily dose…………………….……..……………………… 
 
  Time period?………………………………..……………… 
 
______________________________________________________________ 
 
 2. Anti-epileptics?     Y   /   N 
 
  Name…………………………………………………..………. 
 
  Daily dose..……….…………………………………..………. 
 
  Time period?………………………………………………..… 
. 
______________________________________________________________ 
 
 3. HRT?       Y   /   N 
 
  Name…………………………………………………………… 
 
  Daily dose……………………………………………………… 
 
  Time period?……….……………………….…………………. 
 
______________________________________________________________ 
 
5. Anticoagulants?     Y   /   N 
 
  Name………………………….……………….……………… 
 
  Daily dose……………………………………….………….… 
 
  Time period…………………………………………………… 
 
______________________________________________________________ 
 
 
 
PT NR 
  
 5. Osteoporotic meds?    Y   /   N 
 
  Name……………………………………………………………… 
 
  Daily dose….…………………………………………..………… 
 
  Time period?……………..……………………………………… 
 
 
 6. Any other meds?     Y   /   N 
 
  a. Name……………………………..……………………… 
 
  Daily dose………………..……………………………… 
 
   Time period?………………………..…………………… 
 
 
  b.  Name……………………………………………………… 
 
  Daily dose…………………………...…………………… 
 
   Time period?……………………………………………… 
 
 
  c. Name……………..………………..……………………… 
 
  Daily dose……..…..……………………………………… 
 
   Time period?………………..………….………………… 
 
______________________________________________________________ 
 
PT NR 
 MEDICAL HISTORY 
 
Do you have any of the following diseases? 
 
 1. Lung diseases?      Y  /   N 
 
  Time period……………………………………………. 
______________________________________________________________ 
 
 2. Thyroid?       Y   /   N 
 
  Time period…………………………………………… 
 
3. Chronic renal disease?     Y   /   N 
 
  Time period…………………………………………… 
______________________________________________________________ 
 
 4. Diabetes?       Y   /   N 
 
  Time period…………………………………………… 
______________________________________________________________ 
 
 5. Osteoporosis?      Y   /   N 
 
  Time period………………………………………… 
______________________________________________________________ 
 
 6. Rumatoid arthritis?      Y   /   N 
 
  Time period………………………………………… 
 
 
 7. GIT diseases?      Y   /   N 
 
  Time period………………………………………… 
______________________________________________________________ 
 
 8. Chronic liver disease?     Y   /   N 
 
  Time period………………………………………… 
______________________________________________________________ 
 
 
 
 
PT NR. 
   9.       Any other serious diseases? 
. 
 
  Specify……………………………………………….………………… 
 
 ………………………………………………………………………………..… 
 
______________________________________________________________
PT NR. 
 PATIENT HISTORY 
 
1. Family history of fractures?    Y   /   N 
   
 Specify………………………………………………..……….. 
______________________________________________________________
2. Smoker        Never 
 
Previous 
When stopped?…………….…. 
 
         At present 
 
How much p/d?…………Years?………………..… 
 
______________________________________________________________ 
 
3. Alcohol use:       none 
 
         daily 
 
        weekly 
 
        monthly 
 
 
4. Physical activity: (Compare with 30 min brisk walking/day)   daily 
  
         weekly 
 
         monthly 
 
______________________________________________________________ 
 
5. BMI:………………………………………… 
 
______________________________________________________________ 
 
6. Dairy intake (compare to 250 ml milk/day)    none 
 
         daily 
 
         weekly 
 
 How much?……………………………….. 
 
 
 
 
 
 
 
 
 
 
 
 
 
PT NR. 
 7. < 30 minutes sun exposure/day     Y   /   N 
 
______________________________________________________________ 
 
8. Early menopause (<45 years)     Y   /   N 
 
______________________________________________________________ 
 
9. Previous amenorrhoea (> 3 mnths)    Y   /   N 
 
______________________________________________________________ 
 
10. Hysterectomy       Y   /   N 
 
        Year…………………….. 
 
       Uterus + ovaries 
 
        Only uterus 
 
______________________________________________________________ 
 
11. Pregnancy history: 
 How many pregnancies?………………………… 
 
 Any miscarriage?…………………………..…….. 
 
 How many children?…………………………… 
 
 Did you breastfeed? Y   /   N 
 
 Time period………………..……………….. 
 
______________________________________________________________ 
 
 
 
 
PT NR. 
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APPENDIX B 
 
Ingeligte toestemming/Consent form/Tumellano 
 
 
 INGELIGTE TOESTEMMING 
 
Geagte pasiënt 
'n Navorsingsprojek word beplan deur Mev S.M Pretorius en Prof W.F 
Mollentze om te kyk na die behandeling van osteoporose en daardeur 
pasiëntsorg te verbeter. 
Geen ekstra toetse gaan op u uitgevoer word nie, behalwe die 
Beendigtheidstoets waarvoor u na ons verwys is. 
Om te verseker dat die projek suksesvol sal wees, het ons egter u hulp nodig. 
Al wat van u verlang word is om 'n kort vraelys te beantwoord en dat u 
gewillig sal wees om 2 maande vanaf die ondersoekdatum weer gekontak 
mag word vir opvolgvrae. 
U deelname is vrywillig en enige inligting wat verkry word, sal as konfidensieël 
hanteer word. 
Baie dankie vir u bydrae om hierdie studie suksesvol te maak. 
______________________________________________________________ 
 
Ek,……………………………………………..,geboortedatum………………….…., 
gee hiermee my toestemming om deel te neem aan die navorsingsprojek 
soos aan my verduidelik. 
 
______________________________________________________________ 
 Pasiënt        Datum 
 
 
______________________________________________________________ 
 Getuie        Datum 
 INFORMED CONSENT 
 
Dear patient 
To consider and improve the treatment of osteoporosis, a research project is 
been planned by Mrs S.M Pretorius and Prof. W.F Mollentze. 
No extra tests will be performed other than the Bone Density test which your 
physician originally requested. 
To ensure the success of the project we ask for your co-operation. We 
request only that you answer a few questions and that you will be willing to 
undergo a telephonic follow-up interview within 2 months. 
Your participation is voluntary; therefore any information will be handled 
confidentially. 
 
Thank you for contributing toward the success of the study. 
______________________________________________________________ 
 
I,……………..………………….Date of Birth…………………..………,,give 
permission to take part in the research project as explained to me. 
 
______________________________________________________________ 
  Patient      Date 
 
______________________________________________________________ 
  Witness      Date 
 
 
 
 
 TUMELLANO 
 
Bakudi ba ratehang 
Ho hlokomela le ho ntshetsa pele phekolo ya lefu la masopo, Mme S.M 
Pretorius le Profesa W.F Mollentze ba lotha ho etsa dipatlisiso tse ding. 
Ha ho na diteko tse ding tse tlang ho etswa ho mokudi ntle le sepidi sa ho 
sheba masopo, jwale ka ha ngaka e kapile. 
Ho bona ntshetso-pele ya dipatlisiso tsena, re kopa tshebedisano mmoho. Re 
kopa hore o arabe dipotso tse mmalwa le hore o botswe dipotso ka mohala 
dikgweding tse pedi. 
Ho nka karolo ha hao, hotswa ho wena mme tlhahiso-leseding yohle e tla ba 
lekunutu. 
Re lebohela ho nka karolo ha hao dipatlisisong tsena. 
______________________________________________________________ 
 
Nne………………………………..…..Tsatsi la tlhaho………………………....,ke 
fana ka tumellano ya ho nka karolo dipatlisisong tsena jwale ka ha ke 
hlaloseditswe. 
 
 
______________________________________________________________ 
 Mokudi       Letsatsi 
 
______________________________________________________________ 
 Paki        Letsatsi 
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APPENDIX C 
 
Follow-up questionnaire 
 
 
 
 TELEFONIESE VRAELYS 
 
 
 
 
 
 
 
Staatshospitaal verwysing / Privaat verwysing 
 
1. Het u verwysende dokter enige terugvoer/advies gegee i.v.m. die 
beendigtheidstoets wat op u uitgevoer is?   Ja / Nee 
 
2. Wat het die dokter aan u gesê? (Pasiënt se eie woorde) 
 
………………………………………………………………………………… 
 
3. Het u enige veranderinge aan u lewenstyl na die ondersoek, gemaak? 
 Ja /Nee 
         Dieet 
         Oefening 
        Rookgewoonte 
        Alkoholinname 
         Ander 
 
4.  Het u geneesheer enige middels aan u voorgeskryf?  Ja / Nee 
 ………………………………………….…………………………………… 
 ………………………………………………………………………………. 
 
6.   Gebruik u die middels aan u voorgeskryf?   Ja / Nee 
      Indien NEE, wat is die rede?………………….…………………………….. 
 
PT 
NR DIAGNOSE TELEFOONNR 
 
 
 
 
 
  
7.   Is daar enige instruksies aan u gegee oor toekomstige hantering? Ja/ Nee 
(bv.  opvolg afsprake, opvolg beendigtheid, ens) 
 ………………………………………………………………………………..… 
 
8. Indien pasiënt oorlede is, is afskrif van doodsertifikaat verkry? 
NVT / Ja / Nee 
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APPENDIX D 
 
Data sheet 
  
 
 
 
 
 
 
 
 
A Verwysing  Staat  1               Privaat  2 
B Geslag  Manlik  1              Vroulik  2 
C Kortisoon  Ja  1               Nee  2 
D Anti-epileptiese middels  Ja  1  Nee  2 
E Hormoonvervanging  Ja  1  Nee  2 
F Anti-stol middels  Ja  1  Nee  2 
G Ander meds  Ja  1  Nee  2 
H Longsiekte  Ja  1  Nee  2 
I Tiroied  Ja  1  Nee  2 
J Niersiekte  Ja  1  Nee  2 
K Diabetes  Ja  1  Nee  2 
L Rumatoiede artritis  Ja  1  Nee  2 
N SVK aantasting  Spast.kolon  1 Nee2 Crohn’s3 Maagseer4 verkulitis 5Ulseratcol6 
Gastritis7 
O Lewersiekte  Ja  1  Nee  2 
P Ander ernstige siekte  Mamma Ca 1        Nee  2                Ca ovaria 3 
Q Familiegeskiedenis van frakture  Ja  1  Nee  2 
R Rookgeskiedenis  Nooit  1            Gestaak2 Tans  3 
S Alkoholgebruik  geen 1            daagliks 2      week 3          maand 4 
T Fisiese aktiwiteit>30-minute flink stap 
per dag 
 Ja  1  Nee  2 
 
PATIENT NR:_____________________GESLAG:_________________OUDERDOM_____ 
 
GEWIG:_________________________LENGTE:_________________BMI:_____________ 
  
 
 
 
 
 
 
 
 
 
 
 
U Suiwelinname  ≥250 ml/dag  Ja  1  Nee  2 
V Sonblootstelling<45min/dag  Ja  1  Nee  2 
X Vroeë menopouse (<45 jaar)  Ja  1  Nee  2                  NVT  3 
Y Vorige amenorree (> 3 mnde)  Ja  1  Nee  2                  NVT  3 
Z Histerektomie  Ja  1  Nee  2                  NVT  3 
AA Swangerskap geskiedenis  0    1    2    3    4    5    6                 NVT  7 
AB Geborsvoed  Ja  1  Nee  2                  NVT  3 
AC enige terugvoer/advies  Ja  1  Nee  2 
AD Enige veranderinge self gemaak?  Nee 1   Dieet 2   Oefen 3   Rook 4   Alkohol 5   Dieet+Oef 6 
AE Enige middels voorgeskryf  Ja  1  Nee  2 
AF Gebruik middels voorgeskryf    Ja 1  nie goedkeur deur medies 2   Nie by hos 
beskikbaar 3    Op waglys 4              NVT   5              
Nee 6 
AG Enige instruksies oor toekomstige hantering  Nee    6 mnde opvolg 2   1jaar opvolg  3 
AH T-score total hip   
AI T-score total spine   
AJ Finale resultate   Osteoporose  1  Osteopenies  2 
PT NR 
